We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
DxGen

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Feb 2021 - 28 Feb 2021
Virtual Venue
03 Mar 2021 - 05 Mar 2021
Virtual Venue

Diagnostic Company Acquisition to Ease Market Entry and Shorten Development Time for New Tests

By LabMedica International staff writers
Posted on 15 Sep 2015
Print article
Two North American manufacturers of rapid diagnostic tests are combining in order to pool their products for rapid entry into the diagnostic product market and to boost development of new tests.

NOWDiagnostics Inc. (Springdale, AR, USA) recently completed the acquisition of ZBx Corporation (Toronto, Canada). NOWDiagnostics manufactures and sells a line of blood-based rapid tests that allow health care providers to conduct simple-to-use, highly accurate tests for a variety of ailments and diseases. ZBx Corporation, with a customer base that includes Canada, Europe, Asia, Africa, South America and Mexico, develops and manufactures rapid format, point-of-care diagnostic products in both the human and veterinary fields.

“We are excited about the growth of NOWDiagnostics and what this means for point-of-care testing and the healthcare industry in general. Our acquisition of ZBx, with its deep product portfolio, experienced personnel, and broad capabilities, will help us increase the speed at which we are currently developing our tests,” said Kevin Clark, CEO of NOWDiagnostics. “The tests we are creating have the potential to revolutionize current medical test protocols and to lower costs to insurance companies and, ultimately, consumers.”

Related Links:

NOWDiagnostics
ZBx Corporation



Print article

Channels

Molecular Diagnostics

view channel
Image: FIT (Fecal Immunochemical Test) is a stool test designed to identify possible signs of bowel disease. It detects minute amounts of blood in feces (fecal occult blood) (Photo courtesy of Alpha Laboratories, United Kingdom)

Study Confirms Performance of Rapid Stool Test for Detection of Colorectal Cancer

A recently published paper confirmed the diagnostic performance of the fecal immunochemical test (FIT) for patients with low-risk symptoms of colorectal cancer. The FIT uses specific antibodies to detect... Read more

Pathology

view channel
Image: The Leica Bond III stainer is fully automated Immunohistochemical and In Situ Hybridization (IHC and ISH stainer) (Photo courtesy of Leica Biosystems).

Mismatch Repair/Microsatellite Instability Evaluated Using Cytology Effusion Specimens

DNA mismatch repair (MMR) status is routinely assessed in colorectal and endometrial carcinoma as a method of cancer prevention, surveillance in patients with Lynch syndrome and their families, and for... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.